Company: RVRC
Filing Date: 2025-12-12
Form Type: S-1/A
Source: 0001213900-25-121070
Chunk: 218

Company: Revium Rx.
Filing Date: 2025-12-12
Form: S-1/A
Chunk 218
---
  7,129 |     |          | 100 |     |                                        | 9.61 |     |                           | - |
| Exercisable at July 23, 2024                 |     |                   |  7,129 |     |          | 100 |     |                                        | 9.61 |     |                           | - |

|                                                  |     | Successor         |            |   |     |          |      |     |                             |     |     |                           |   |
|                                                  |     | Number of options |            |   |     | Weighted 
 average  
 exercise 
 price    |      |     | Weighted                    
 average                     
 remaining contractual terms 
 (in years)                  |     |     | Aggregate intrinsic value |   |
| Outstanding at July 24, 2024                     |     |                   |  7,020,000 |   |     |          | 0.18 |     |                             | 6.1 |     |                           | - |
| Grants                                           |     |                   |    740,000 |   |     |          |  0.3 |     |                             |  10 |     |                           | - |
| Exercised                                        |     |                   | (2,800,000 | ) |     |          |      |     |                             |     |     |                           |   |
| Outstanding at December 31, 2024                 |     |                   |  4,960,000 |   |     |          |  0.3 |     |                             | 6.1 |     |                           | - |
| Vested and expected to vest at December 31, 2024 |     |                   |  4,960,000 |   |     |          |  0.3 |     |                             | 6.1 |     |                           | - |
| Exercisable at December 31, 2024                 |     |                   |  3,790,000 |   |     |          | 0.38 |     |                             | 5.1 |     |                           | - |

<div align='center'>F-29</div>

REVIUM RX.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

NOTE 9 – TAXES ON INCOME

| a. | Tax rates applicable to the Company: |

Taxable income